Nasus Pharma Business Summary

Nasus Pharma Ltd (NSRX) is a clinical-stage biopharmaceutical company that generates value through the development and future commercialization of its proprietary Nasax® powder-based intranasal (PBI) technology. The company’s business model focuses on disrupting the emergency medicine market by replacing traditional injectables and liquid sprays with needle-free, rapid-onset dry powder formulations. Its primary business segments are categorized by therapeutic application: the lead NS002 program for anaphylaxis (epinephrine), the NS001 program for opioid overdose (naloxone), and a preclinical pipeline targeting cardiovascular, metabolic, and anti-emetic indications. Nasus competes directly with ARS Pharmaceuticals (Neffy), Viatris (EpiPen), and Emergent BioSolutions (Narcan), positioning itself as a superior alternative by offering enhanced drug stability and significantly faster absorption rates compared to existing liquid-based and intramuscular standards of care. The company was founded in 2019 by a team of seasoned life sciences entrepreneurs, led by Executive Chairman Udi Gilboa and Chief Development Officer Dr. Dalia Megiddo, both of whom have extensive pedigrees in clinical development and biotech exits. The executive leadership includes CEO Dan Teleman, who brings over two decades of pharmaceutical management experience, and Executive Vice President and CFO Eyal Rubin, the former CFO of Protalix BioTherapeutics who was appointed in late 2025 to spearhead the company’s capital strategy. Nasus is supported by a high-profile Board of Directors featuring industry veterans such as Dr. Sharon Shacham, co-founder of Karyopharm Therapeutics, and Isaac Israel. The firm recently strengthened its balance sheet in February 2026 through a $15 million private placement involving both institutional investors and board members to fund the pivotal clinical advancement of its lead epinephrine candidate.